ALX ONCOLOGY HOLDINGS INC Pre-Tax Income
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Pre-Tax Income of -$101.69 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-09
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2021-12-31 was -$28.46M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2021-09-30 was -$24.57M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2021-06-30 was -$16.27M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2021-03-31 was -$14.19M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$101.69M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$134.85M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$160.81M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$123.42M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$101.69M 10-K · filed 2026-03-09 | |||
| 2024-12-31 | -$134.85M 10-K · filed 2026-03-09 | |||
| 2023-12-31 | -$160.81M 10-K · filed 2026-03-09 | |||
| 2022-12-31 | -$123.42M 10-K · filed 2025-03-06 | |||
| 2021-12-31 | -$28.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$53.02M derived: sum of 2 quarters · filed 2024-03-07 | -$69.30M derived: sum of 3 quarters · filed 2024-03-07 | -$83.48M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$24.57M 10-Q · filed 2021-11-12 | -$40.84M derived: sum of 2 quarters · filed 2021-11-12 | -$55.02M 10-Q · filed 2021-11-12 | -$73.62M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | -$16.27M 10-Q · filed 2021-08-12 | -$30.46M 10-Q · filed 2021-08-12 | -$49.05M derived: sum of 3 quarters · filed 2023-03-09 | -$59.20M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | -$14.19M 10-Q · filed 2021-05-17 | -$32.78M derived: sum of 2 quarters · filed 2023-03-09 | -$42.92M derived: sum of 3 quarters · filed 2023-03-09 | -$54.23M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | -$18.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$28.74M derived: sum of 2 quarters · filed 2023-03-09 | -$40.05M derived: sum of 3 quarters · filed 2023-03-09 | -$45.50M 10-K · filed 2023-03-09 |
| 2020-09-30 | -$10.15M 10-Q · filed 2021-11-12 | -$21.46M derived: sum of 2 quarters · filed 2021-11-12 | -$26.91M 10-Q · filed 2021-11-12 | -$34.66M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$11.31M 10-Q · filed 2021-08-12 | -$16.76M 10-Q · filed 2021-08-12 | -$24.52M derived: sum of 3 quarters · filed 2022-02-28 | -$27.55M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$5.45M 10-Q · filed 2021-05-17 | -$13.21M derived: sum of 2 quarters · filed 2022-02-28 | -$16.24M derived: sum of 3 quarters · filed 2022-02-28 | -$20.43M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$10.79M derived: sum of 2 quarters · filed 2022-02-28 | -$14.98M derived: sum of 3 quarters · filed 2022-02-28 | -$19.21M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$3.04M 10-Q · filed 2020-11-12 | -$7.22M derived: sum of 2 quarters · filed 2020-11-12 | -$11.45M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$4.19M 10-Q · filed 2020-08-27 | -$8.42M 10-Q · filed 2020-08-27 | ||
| 2018-12-31 | -$13.69M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |